Bildiri Koleksiyonu
Bu koleksiyon için kalıcı URI
Güncel Gönderiler
Öğe Pioneering precision: unraveling cellular bioenergetics with ph-control(2024) Ghaffari Zaki, Asal; Miri, Seyed Mohammad; Çimen, Şeyma; Akgül Çağlar, Tuba; Yiğit, Esra Nur; Aydın, Mehmet Şerif; Öztürk, Gürkan; Eroğlu, Emrah[Abstract Not Available]Öğe Hyper7 biosensor associate with proteomic shifts related to oxidative stress in endothelial cells(2024) Barakat, Sarah; Çimen, Şeyma; Miri, Seyed Mohammad; Vatandaşlar, Emre; Kök, Kıvanç; Öztürk, Gürkan; Eroğlu, Emrah[Abstract Not Available]Öğe The relationship between mitochondrial oxidative stress and huntington's disease progression(2024) Yiğit, Esra Nur; Aydın, Mehmet Şerif; Eroğlu, Emrah; Öztürk, Gürkan[Abstract Not Available]Öğe Investigating the roles of micrornas / lncrnas in characterizing breast cancer subtypes and prognosis(2023) Pek, Reyhan Zeynep; Zavalsız, Muhammed Talha; Serdar, Melis; Alhajj, Lama; Alhajj, Sleiman; Sailunaz, Kashfia; Özyer, Tansel; Rokne, Jon; Alhajj, RedaMolecular subtyping is a method of separating tumor clusters in a cancer type with common features according to molecular data and classification models. Genome datasets are taken from many different people and some genetic material, more precisely genetic markers, are obtained to predict the presence of a disease. In addition, breast cancer occurs due to mutation or modification observed in cells. miRNAs and lncRNAs take participation in cell cycle, regulation, and even chromatic inhibition of cell. For example, miRNAs function in cell cycle regulation as the degradation of mRNAs. Therefore, the aim of this work is to investigate the roles of miRNAs and lncRNAs in prognosis and characterizing the subtypes of Breast Cancer.Öğe Cross-sectional analysis of cardiovascular disease and risk factors in patients with spondyloarthritis: A real-life evidence from biostar nationwide registry(BMJ Publishing Group, 2023) Duruöz, Mehmet Tuncay; Bodur, Hafize; Ataman, Şebnem; Gürer, Gülcan; Akgül, Özgür; Çay, H. F.; Çapkın, Erol; Altan İnceoğlu, LaleBackground: Association between spondyloarthritis and cardiovascular (CV) diseases is a complex issue with variable outcomes. Objectives: This study aimed to assess the prevalence rates of CV diseases and to analyze the impact of CV risk factors on CV disease in patients with spondyloarthritis. Methods: A multi-center cross-sectional study using BioSTAR (Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs Registry) database was performed on patients with spondyloarthritis. Socio-demographic, laboratory and clinical, data were collected. Patients with and without major adverse cardiovascular events (MACE) were grouped as Group 1 and Group 2.The primary outcome was the prevalence rates of CV disease and CV risk factors in the overall group. The secondary outcome was the difference in socio-demographic and clinical characteristics between the groups and predictive risk factors for CV disease.Öğe Prevalence of cardiovascular diseases and traditional cardiovascular risk factors in patients with rheumatoid arthritis: A real-life evidence from biostar nationwide registry(BMJ Publishing Group, 2023) Duruöz, Mehmet Tuncay; Ataman, Şebnem; Bodur, Hafize; Çay, H. F.; Alkan Melikoğlu, Meltem; Akgül, Özgür; Çapkın, Erol; Gürer, Gülcan; Çevik, Remzi; Göğüş, Feride Nur; Kamanlı, Ayhan; Yurdakul, Fatma Gül; Yağcı, İlker; Rezvani, Aylin; Altan İnceoğlu, LaleBackground: Patients with rheumatoid arthritis (RA) have increased morbidity and mortality due to cardiovascular (CV) comorbidities. Objectives: The association of CV diseases (CVD) and traditional CV risk factors have been debated, depending on patient and RA characteristics. This study aimed to find the prevalence of CVD and CV risk factors in patients with RA. Methods: A multi-center cross-sectional study was performed on RA patients using the BioSTAR (Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs Registry). Socio-demographic, clinical, and follow-up data were collected. Patients with and without major adverse cardiovascular events (MACE) were grouped as Group 1 and Group 2. Prevalence rates of CVD and traditional CV risk factors were the primary outcomes. Secondary outcomes were the differences in the clinical characteristics between patients with and without CVD.Öğe Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.(Lippincott Williams & Wilkins, 2023) Özcan, Muhit; Lee, Seung Tae; Mensah, Felix; Modi, Dipenkumar; Fossa, Alexander; Kim, Won Seog; Paszkiewicz-Kozik, Ewa; Sevindik, Ömür Gökmen; Lavie, David[Abstract Not Available]Öğe A multicenter propensity score matched pair study in 313 patients comparing percutaneous nephrolithotomy versus retrograde intra renal surgery for management of urolithiasis in calyceal diverticulum(Elsevier, 2023) Lim, E. J.; Castellani, D.; Somani, B. K.; Fong, K. Y.; Ragoori, D.; Mani, Mriganka S.; Soebhali, B.; Gauhar, V.[Abstract Not Available]Öğe Does gender influence Extracorporeal Shock Wave Lithotripsy practice (ESWL)? Results form a global survey(Elsevier, 2023) Gauhar, V.; Koçak, Mehmet; Dasgupta, R.; Ganpule, A.; Chawla, A.; Lim, E. J.; de la Rosette, Jean J. M. C. H.[Abstract Not Available]Öğe Decision regret analysis of patients opting for early ureteroscopy versus trial of medical expulsive therapy after shared decision making for management of ureteric calculi ? 10mm: Interim results from the DRAUMET study(Elsevier, 2023) Singh, A.; Chawla, A.; de la Rosette, Jean J. M. C. H.; Choudhary, A.; Pillai, S.; Hegde, P.; Abhishek, G. V. S.[Abstract Not Available]Öğe European Association of Urology (EAU) Testicular Cancer Guidelines Panel: A new prognostic factor risk group classification for patients with clinical stage 1 seminoma in active surveillance.(Lippincott Williams & Wilkins, 2023) Boormans, Joost; Sylvester, Richard J.; Anson-Cartwright, Lynn; Glicksman, Rachel; Hamilton, Robert James; Daugaard, Gedske; Lauritsen, Jakob; Wagner, Thomas; Avuzzi, Barbara; Nicolai, Nicola; Aparicio, Jorge; del Muro, Xavier Garcia; del Pilar Laguna Pes, Maria[Abstract Not Available]Öğe Diffusion-based hierarchical multi-label object detection to analyze panoramic dental X-rays(Springer Science and Business Media Deutschland GmbH, 2023) Hamamcı, İbrahim Ethem; Er, Sezgin; Simsar, Enis; Sekuboyina, Anjany; Gündoğar, Mustafa; Stadlinger, Bernd; Mehl, Albert; Menze, BjoernDue to the necessity for precise treatment planning, the use of panoramic X-rays to identify different dental diseases has tremendously increased. Although numerous ML models have been developed for the interpretation of panoramic X-rays, there has not been an end-to-end model developed that can identify problematic teeth with dental enumeration and associated diagnoses at the same time. To develop such a model, we structure the three distinct types of annotated data hierarchically following the FDI system, the first labeled with only quadrant, the second labeled with quadrant-enumeration, and the third fully labeled with quadrant-enumeration-diagnosis. To learn from all three hierarchies jointly, we introduce a novel diffusion-based hierarchical multi-label object detection framework by adapting a diffusion-based method that formulates object detection as a denoising diffusion process from noisy boxes to object boxes. Specifically, to take advantage of the hierarchically annotated data, our method utilizes a novel noisy box manipulation technique by adapting the denoising process in the diffusion network with the inference from the previously trained model in hierarchical order. We also utilize a multi-label object detection method to learn efficiently from partial annotations and to give all the needed information about each abnormal tooth for treatment planning. Experimental results show that our method significantly outperforms state-of-the-art object detection methods, including RetinaNet, Faster R-CNN, DETR, and DiffusionDet for the analysis of panoramic X-rays, demonstrating the great potential of our method for hierarchically and partially annotated datasets. The code and the datasets are available at https://github.com/ibrahimethemhamamci/HierarchicalDet.Öğe The effect of DNA tension on CRISPR/Cas12a cleavage can be reversible(Cell Press, 2023) Üçüncüoğlu, Süleyman[Abstract Not Available]Öğe Segmental resection for ureter urothelial carcinoma is safe as radical nephroureterectomy(Elsevier, 2023) Liu, K.; Zhao, H.; Chen, X.; Ng, C.; Teoh, J. Y.; del Pilar Laguna Pes, Maria; de la Rosette, Jean J. M. C. H.Introduction & Objectives: Kidney-sparing surgery (KSS) seems inferior to radical nephroureterectomy (RNU) in recurrence-free survival (RFS). However, there is limited data regarding the potential influence of the location of the upper tract urothelial carcinoma (UTUC). The current study aims to provide further evidence by the largest UTUC registry.Öğe Retrospective analysis of Turkish AML registry database, on behalf of AML working group of Turkish society of hematology(American Society of Hematology, 2022) Karakuş, Volkan; Sevindik, Ömür Gökmen; Karataş, Aylin; Yenihayat, Emel Merve; Polat, Merve Gökçen; Çelik, Serhat; Pınar, İbrahim Ethem; Alacacıoğlu, İnciAbstract Introduction: To investigate the demographics and treatment details of the acute myeloid leukemia (AML) patients who were diagnosed and followed up in Turkey. Methods: Patients who were recorded on the database of Turkish AML Registry project were included in this study retro- spectively if they were diagnosed before 1st of Jan 2022. Demographics, patient, and disease related parameters both at the time of diagnosis and at the follow up and treatment outcomes were presented.Öğe A case series of CML patients who were presented with isolated thrombocytosis(American Society of Hematology, 2022) Karakuş, Volkan; Aslan, Vedat; Parça, Güleycan; Sevindik, Ömür Gökmen; Keklik Karadağ, Fatma; Kurtoğlu, Erdal; Saydam, GürayPer WHO 2016 and 2022 (5th ed.) myeloproliferative disease guidelines, Chronic Myeloid Leukemia (CML) is classified under two major groups according to the presence of bcr-abl translocation; these groups require different treatment approaches and show clinical presentation heterogeneity. Treatment agents such as tyrosine kinase inhibitors (Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib, Radotinib), Omacetaxine and Asciminib have been used in the treatment of Bcr abl positive CML according to the patient's clinic and mutation status. According to the IRIS study, a study evaluating CML patients treatment response to imatinib, the major molecular response was 33.3% at 3 months, the major molecular response was 48% at 6 months, and the major molecular response was 62.1% at 12 months; furthermore, the rate of achieving a complete molecular response at 12 months was 94.9% (4). In patients who was treated with imatinib as first line therapy, the rate of transformation to accelerated or blastic phase at 18 months was 0.9% in the MMR group and 9.9% in the non-MMR group. In "conventional" CML patients, high leukocyte counts may be accompanied by thrombocytosis; though presentation with only thrombocytosis without leukocytosis is hardly described so far. In this poster presentation, we introduced 7 cases who initially presented with isolated thrombocytosis and then diagnosed with Ph(+) CML. This study was conducted in three adult hematology centers from Antalya, Izmir and Istanbul. 400 patients followed in these centers were reviewed retrospectively; seven patients presented with isolated thrombocytosis were identified. Demographic characteristics, diagnostic findings, and risk scores of these patients were evaluated (Tablo 1). Eln 2013 response criteria were used for evaluation of response for 3rd, 6th, 12th. monthly responses (Figure 1). Here we present 7 CML patients without leukocytosis who were diagnosed with marked thrombocytosis. The patients had similar symptoms and physical examination with no obvious splenomegaly or thrombosis. All of the patients had minimal basophilia and normal peripheral smear findings. All patients responded well to imatinib therapy. During follow up patients who maintained their MMR achieve had a better clinical course and prognosis compared to other CML patients.Öğe Assesment of patient's perspective on treatment free remission in CML: A Turkish multicenter cohort(American Society of Hematology, 2022) Mutlu, Yaşa Gül; Güvenç, Birol; Serin, İstemi; Balık Aydın, Berrin; Alacacıoğlu, İnci; Güven, Serkan; Sevindik, Ömür GökmenTreatment free remission (TFR) is one of the main goals of therapy in Chronic Myeloid Leukemia (CML). Patient perspective and expectations have an indicative effect on discontinuation decisions. We analyzed 116 CML patients' perspective on TFR and factors that associated with willingness for tyrosine kinaz inhibitor (TKI) discontinuation from four different center in Turkey based on a national survey. Patients in our cohort had 7.8% awareness of TFR and after brief information willingness to attempt TFR has been reached to 58.9% in all population. Shorter disease duration was associated with enhanced willingness to attempt discontinuation in multivariate analyses (p=0.031). Most common patient related limitation for TKI discontinuation decision was anxiety about disease relaps and TKI resistance. Even disease relaps in TFR means molecular and detectable with close monitoring, patients still had considerable concerns about TKI discontinuation.Öğe Comparison of efficacy and safety of generic plerixafor vs original plerixafor in the mobilization of myeloma patients(American Society of Hematology, 2022) Sevindik, Ömür Gökmen; Bilgen, Hülya; Serin, İstemi; Melek, Elif; Karakuş, Volkan; Çerçi, Kübra; Mutlu, Yaşa Gül; Balık Aydın, Berrin; Sadri, Sevil; Beköz, Hüseyin Saffet; Kaynar, LeylagülIntroduction The commonest indication for an Autologous Stem Cell Transplantation (ASCT) is still Multiple Myeloma. A successful mobilization of hematopoietic stem cells (HSC) is a sine qua non of ASCT. The introduction of Plerixafor, which is a partial agonist of the alfa-chemokine receptor CXCR4 has added an important value and impact on mobilization. Plerixafor is successfully integrated into both growth factor-only and cyclophosphamide and growth factor mobilization strategies with significantly reducing the mobilization failure rate in myeloma patients. In addition, plerixafor + G-CSF has also been shown to successfully mobilize the majority of patients who previously failed to mobilize with either growth factor alone or in combination with chemotherapy. Even a Just-in-Time algorithm which induces plerixafor in patients who lacks a certain threshold of CD34 positive HSCs on the day of mobilization led to a cost-effective and successful mobilization with highly restricted rates of mobilization failure. In this study we tried to demonstrate the efficacy and safety of a novel generic Plerixafor (Pleksor - Gen Ilac) and to compare it with original one (Mozobil - Sanofi) in a retrospective manner. Method Patients who were transplanted in two centers who adopted the same mobilization standard operating procedures (SOP) were included in the study. An age and sex matched cohort of patients who received Mozobil (from 2020-2022 - Group A) were compared with the ones who received Pleksor (2021-2022 Group B) as a Just-in-Time conjunct to GCSF alone or chemo mobilization. Poor mobilization was defined as a final yield of 2 million CD34 positive HSCs per kg. Our aim was to collect enough stem cells for at least two ASCTs, thus our current SOP's indicated a minimum CD34 positive HSC threshold of at least 4 million per kg and an ideal HSC threshold of 6 million per kg. Results A total of 28 patients were included and they were equally distributed among Group A (n=14) and B (n=14). Median age of the patients at the time of mobilization were as follows, 60 (35-72) in Group A and 61 (38-70) in Group B. 14 patients who received Pleksor achieved a median yield of 8.40 million CD34 positive HSCs per kg (4.8-21) and the patients who received Mozobil have ended with a yield of 6.7 million CD34 positive HSCs per kg (4.5-13) (p=0.210). None of the patients in both groups were named to be a poor mobilizer according to the threshold of 2 million CD34 positive HSCs per kg but 3 of the patients in Group A and 2 of the patients in Group B ended with a yield of 6 million CD34 positive cells which was below to the ideal threshold for two transplants. Regarding lenalidomide exposure before mobilization, history of radiotherapy, line of the therapies received before mobilization, number of leukapheresis and the mobilization policy (chemo vs gcsf alone) there were no statistically significant difference between two groups (p=0.120, 0.702, 0.842, 0.769 and 0.420 respectively). The median neutrophil engraftment time in days were as follows for Group A and B, 11(10-14) vs 11 (10-16), p=0.541 and the median platelet engraftment time in days were 17 (10-30) in Group A and 16 (10-28) in Group B with a p value of 0.571. In none of the cases any specific side effects were noted which could be attributable to Pleksor or Mozobil. Conclusion Our study demonstrated a comparable efficacy of a generic form of Plerixafor when compared with the originator. This would lead to a decrease in the cost of total process of mobilization with a similar efficacy and toxicity profile. We are now planning to initiate a prospective trial to validate these results in a larger patient population. Up to our knowledge this is the first study comparing the efficacy of a generic Plerixafor in a sole myeloma patient cohort.Öğe An assessment of cardiovascular health risks in people working from home during the pandemic period: PANDEV-KALP study(AVES, 2022) Tazegül, Gökhan; Aydın, Volkan; Kıraç Aksuna, Gülin; Yücel, Rıfat; Dik, Bülent; Aksoy, Şevket; Koç, Erdal; Tiryaki, Ali Rıza; Kurt, İbrahim; Görk, Atilla; Erdoğan, Turgay; Aysevinç, Berrin; Çeçen Düzel, Songül; Topçu, Mümüne; Akıcı, Ahmet; Fak, Ali Serdar[Abstract Not Available]Öğe Pancreatic tumor detection by convolutional neural networks(Institute of Electrical and Electronics Engineers Inc., 2022) Zavalsız, Muhammed Talha; Alhajj, Sleiman; Sailunaz, Kashfia; Özyer, Tansel; Alhajj, RedaArtificial Intelligence and its sub-branches like Machine Learning (ML) and Deep Learning (DL) applications have the potential to have positive effects that can directly affect human life. Medical imaging provides a way for the internal structure of the human body to be visible with various methods. With DL models, cancer detection, which is one of the most lethal diseases in the world, from medical images can be made possible with high accuracy. The main objective of this paper is to detect Pancreatic Cancer, which is one of the cancer types with the highest fatality rate, from a dataset of Computed Tomography (CT) images, which is one of the medical imaging techniques and has an effective structure in Pancreatic Cancer imaging. The designed DL model is integrated into the Flask application to develop a web application. With this application, early diagnosis of pancreatic cancer can be achieved, which progresses insidiously and therefore does not spread to neighboring tissues and organs when the treatment process is started. Due to the abundance of medical images reviewed by medical professionals, this application can assist radiologists and other specialists in Pancreatic Tumor detection.
